Here's one real example of how NoxReg turns a dense agency notice into something your team can act on in seconds — not hours of reading.
1. What the agency actually publishes
"The Pharmacovigilance Risk Assessment Committee (PRAC) has completed its review of a signal concerning GLP-1 receptor agonist products and has recommended an update to the product information to include a new warning regarding..." — 640 words of dense regulatory text, no structure, no scoring, no context on what to do next.
2. What NoxReg shows your team
14 March 2026
AI Summary
PRAC has recommended a product information update for GLP-1 receptor agonists following a new pharmacovigilance signal. Marketing authorization holders will need to submit variation applications within the standard implementation timeline.
Action Recommendation
Review your GLP-1 product labeling against the new PRAC wording. Flag for your PV and regulatory affairs teams — a Type II variation submission is likely required. Recommended deadline for internal review: within 2 weeks, ahead of the formal implementation window.
Product type
Drug, Biologic
Relevant to
Regulatory Affairs, Pharmacovigilance, Medical Affairs
AI-generated content (OpenAI). All summaries, importance scores, and action recommendations are AI-generated and must be reviewed by a qualified regulatory professional before use in any regulated activity. NoxReg is not a substitute for regulatory advice.
Start free and see your own dashboard fill up with real, classified updates from day one.